Interaction of the Transactivation Domain of B-Myb with the TAZ2 Domain of the Coactivator p300: Molecular Features and Properties of the Complex

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Oka, Ojore ^a   Waters, Lorna C ^a   Strong, Sarah L ^a   Dosanjh, Nuvjeevan S ^a   Veverka, Vaclav ^a   Muskett, Frederick W ^a   Renshaw, Philip S ^a   Klempnauer, Karl Heinz ^b   Carr, Mark D ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COACTIVATOR P300; DNA; POLYPEPTIDE; PROTEIN; STAT1 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR B MYB; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CELL CYCLE REGULATION; CIRCULAR DICHROISM; COMPLEX FORMATION; FLUORESCENCE SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN INTERACTION; PROTEIN STRUCTURE; TAZ2 DOMAIN; TRANSACTIVATION DOMAIN; TRANSCRIPTION INITIATION; VERTEBRATE;

CELL CYCLE PROTEINS; CIRCULAR DICHROISM; E1A-ASSOCIATED P300 PROTEIN; HUMANS; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; TRANS-ACTIVATORS;

VERTEBRATA;

EID: 84871792510     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052906     Document Type: Article

References (72)

1. Bannister AJ, Kouzarides T, (1996) The CBP co-activator is a histone acetyltransferase. Nature 384: 641-643.
2. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y, (1996) The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87: 953-959.
3. Goodman RH, Smolik S, (2000) CBP/p300 in cell growth, transformation, and development. Genes Dev 14: 1553-1577.
4. Janknecht R, Hunter T, (1996) Transcription- A growing coactivator network. Nature 383: 22-23.
5. Nomura N, Takahashi M, Matsui M, Ishii S, Date T, et al. (1988) Isolation of Human cDNA Clones of Myb-Related Genes, A-Myb and B-Myb. Nucleic Acids Res 16: 11075-11089.
6. Joaquin M, Watson RJ, (2003) Cell cycle regulation by the B-Myb transcription factor. Cell Mol Life Sci 60: 2389-2401.
7. Oh IH, Reddy EP, (1999) The Myb gene family in cell growth, differentiation and apoptosis. Oncogene 18: 3017-3033.
8. Sala A, Watson R, (1999) B-Myb protein in cellular proliferation, transcription control, and cancer: Latest developments. J Cell Physiol 179: 245-250.
9. Saville MK, Watson RJ, (1998) The cell-cycle regulated transcription factor B-Myb is phosphorylated by cyclin A/Cdk2 at sites that enhance its transactivation properties. Oncogene 17: 2679-2689.
10. Biedenkapp H, Borgmeyer U, Sippel AE, Klempnauer KH, (1988) Viral Myb oncogene encodes a sequence-specific DNA-binding activity. Nature 335: 835-837.
11. Nakagoshi H, Takemoto Y, Ishii S, (1993) Functional domains of the human-B-Myb gene-product. J Biol Chem 268: 14161-14167.
12. Ansieau S, Kowenz-Leutz E, Dechend R, Leutz A, (1997) B-Myb, a repressed trans-activating protein. J Mol Med 75: 815-819.
13. Lane S, Farlie P, Watson R, (1997) B-Myb function can be markedly enhanced by cyclin A-dependent kinase and protein truncation. Oncogene 14: 2445-2453.
14. Sala A, Kundu M, Casella I, Engelhard A, Calabretta B, et al. (1997) Activation of human B-MYB by cyclins. Proc Natl Acad Sci USA 94: 532-536.
15. Schubert S, Horstmann S, Bartusel T, Klempnauer KH, (2004) The cooperation of B-Myb with the coactivator p300 is orchestrated by cyclins A and D1. Oncogene 23: 1392-1404.
16. Ziebold U, Bartsch O, Marais R, Ferrari S, Klempnauer KH, (1997) Phosphorylation and activation of B-Myb by cyclin A-Cdk2. Curr Biol 7: 253-260.
17. Johnson LR, Johnson TK, Desler M, Luster TA, Nowling T, et al. (2002) Effects of B-Myb on gene transcription: phosphorylation-dependent activity ans acetylation by p300. J Biol Chem 277: 4088-4097.
18. Li XL, McDonnell DP, (2002) The transcription factor B-Myb is maintained in an inhibited state in target cells through its interaction with the nuclear corepressors N-CoR and SMRT. Mol Cell Biol 22: 3663-3673.
19. Foos G, Natour S, Klempnauer KH, (1993) TATA-box dependent transactivation of the human HSP70 promoter by Myb proteins. Oncogene 8: 1775-1782.
20. Kamano H, Klempnauer KH, (1997) B-Myb and cyclin D1 mediate heat shock element dependent activation of the human HSP70 promoter. Oncogene 14: 1223-1229.
21. Watson RJ, Robinson C, Lam EWF, (1993) Transcription regulation by murine B-Myb is distinct from that by c-Myb. Nucleic Acids Res 21: 267-272.
22. Bartusel T, Schubert S, Klempnauer KH, (2005) Regulation of the cyclin D1 and cyclin A1 promoters by B-Myb is mediated by Sp1 binding sites. Gene 351: 171-180.
23. Osterloh L, von Eyss B, Schmit F, Rein L, Hubner D, et al. (2007) The human synMuv-like protein LIN-9 is required for transcription of G2/M genes and for entry into mitosis. EMBO J 26: 144-157.
24. Pilkinton M, Sandoval R, Colamonici OR, (2007) Mammalian Mip/LIN-9 interacts with either the p107, p130/E2F4 repressor complex or B-Myb in a cell cycle-phase-dependent context distinct from the Drosophila dREAM complex. Oncogene 26: 7535-7543.
25. Sala A, Saitta B, De Luca P, Cervellera MN, Casella I, et al. (1999) B-Myb transactivates its own promoter through SP1-binding sites. Oncogene 18: 1333-1339.
26. Zhu WC, Giangrande PH, Nevins JR, (2004) E2Fs link the control of G1/S and G2/M transcription. EMBO J 23: 4615-4626.
27. Dai P, Akimaru H, Tanaka Y, Hou DX, Yasukawa T, et al. (1996) CBP as a transcriptional coactivator of c-Myb. Genes Dev 10: 528-540.
28. Facchinetti V, Loffarelli L, Schreek S, Oelgeschlager M, Luscher B, et al. (1997) Regulatory domains of the A-Myb transcription factor and its interaction with the CBP/p300 adaptor molecules. Biochem J 324: 729-736.
29. Oelgeschlager M, Janknecht R, Krieg J, Schreek S, Luscher B, (1996) Interaction of the co-activator CBP with Myb proteins: Effects on Myb-specific transactivation and on the cooperativity with NF-M. EMBO J 15: 2771-2780.
30. De Guzman RN, Liu HY, Martinez-Yamout M, Dyson HJ, Wright PE, (2000) Solution structure of the TAZ2 (CH3) domain of the transcriptional adaptor protein CBP. J Mol Biol 303: 243-253.
31. Renshaw PS, Panagiotidou P, Whelan A, Gordon SV, Hewinson RG, et al. (2002) Conclusive evidence that the major T-cell antigens of the Mycobacterium tuberculosis complex ESAT-6 and CFP-10 form a tight, 1:1 complex and characterization of the structural properties of ESAT-6, CFP-10, and the ESAT-6*CFP-10 complex. Implications for pathogenesis and virulence. J Biol Chem 277: 21598-21603.
32. Waters L, Yue B, Veverka V, Renshaw P, Bramham J, et al. (2006) Structural diversity in p160/CREB-binding protein coactivator complexes. J Biol Chem 281: 14787-14795.
33. Toribio F, Martinez-Lara E, Pascual P, Lopez-Barea J, (1996) Methods for purification of glutathione peroxidase and related enzymes. J Chromatogr B Biomed Appl 684: 77-97.
34. Cordingley MG, Callahan PL, Sardana VV, Garsky VM, Colonno RJ, (1990) Substrate requirements of human rhinovirus 3C protease for peptide cleavage in vitro. J Biol Chem 265: 9062-9065.
35. Walker PA, Leong LE, Ng PW, Tan SH, Waller S, et al. (1994) Efficient and rapid affinity purification of proteins using recombinant fusion proteases. Biotechnology (N Y) 12: 601-605.
36. Bodenhausen G, Ruben DJ, (1980) Natural abundance N-15 NMR by enhanced heteronuclear spectroscopy. Chem Phys Lett 69: 185-189.
37. Wittekind M, Mueller L, (1993) HNCACB, a high-sensitivity 3D NMR experiment to correlate amide-proton and nitrogen resonances with the alpha-carbon and beta-carbon resonances in proteins. J Magn Reson B 101: 201-205.
38. Grzesiek S, Bax A, (1993) Amino-acid type determination in the sequential assignment procedure of uniformly C-13/N-15-enriched proteins. J Biomol NMR 3: 185-204.
39. Grzesiek S, Dobeli H, Gentz R, Garotta G, Labhardt AM, et al. (1992) 1H, 13C, and 15N NMR backbone assignments and secondary structure of human interferon-gamma. Biochemistry 31: 8180-8190.
40. Piotto M, Saudek V, Sklenar V, (1992) Gradient-tailored excitation for single-quantum NMR-spectroscopy of aqueous-solutions. J Biomol NMR 2: 661-665.
41. Waters LC, Veverka V, Bohm M, Schmedt T, Choong PT, et al. (2007) Structure of the C-terminal MA-3 domain of the tumour suppressor protein Pdcd4 and characterisation of its interaction with eIF4A. Oncogene 26: 4941-4950.
42. Muskett F, Frenkiel T, Feeney J, Freedman R, Carr M, et al. (1998) High resolution structure of the N-terminal domain of tissue inhibitor of metalloproteinases-2 and characterization of its interaction site with matrix metalloproteinase-3. J Biol Chem 273: 21736-21743.
43. Veverka V, Crabbe T, Bird I, Lennie G, Muskett FW, et al. (2008) Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR. Oncogene 27: 585-595.
44. Williamson RA, Carr MD, Frenkiel TA, Feeney J, Freedman RB, (1997) Mapping the binding site for matrix metalloproteinase on the N-terminal domain of the tissue inhibitor of metalloproteinases-2 by NMR chemical shift perturbation. Biochemistry 36: 13882-13889.
45. Wishart DS, Sykes BD, (1994) The C-13 Chemical-Shift Index- a simple method for the identification of protein secondary structure using C-13 chemical-shift data. J Biomol NMR 4: 171-180.
46. Cornilescu G, Delaglio F, Bax A, (1999) Protein backbone angle restraints from searching a database for chemical shift and sequence homology. J Biomol NMR 13: 289-302.
47. Jenkins LM, Yamaguchi H, Hayashi R, Cherry S, Tropea JE, et al. (2009) Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation. Biochemistry 48: 1244-1255.
48. Lee MS, Palmer AG 3rd, Wright PE (1992) Relationship between 1H and 13C NMR chemical shifts and the secondary and tertiary structure of a zinc finger peptide. J Biomol NMR 2: 307-322.
49. Iyer KS, Klee WA, (1973) Direct Spectrophotometric Measurement of Rate of Reduction of Disulfide Bonds- Reactivity of Disulfide Bonds of Bovine Alpha-Lactalbumin. J Biol Chem 248: 707-710.
50. Horstmann S, Ferrari S, Klempnauer KH, (2000) Regulation of B-Myb activity by cyclin D1. Oncogene 19: 298-306.
51. Uversky VN, Gillespie JR, Fink AL, (2000) Why are "natively unfolded" proteins unstructured under physiologic conditions? Proteins 41: 415-427.
52. Garner E, Cannon P, Romero P, Obradovic Z, Dunker AK, (1998) Predicting Disordered Regions from Amino Acid Sequence: Common Themes Despite Differing Structural Characterization. Genome Inform Ser Workshop Genome Inform 9: 201-213.
53. Radhakrishnan I, PerezAlvarado GC, Parker D, Dyson HJ, Montminy MR, et al. (1997) Solution structure of the KIX domain of CBP bound to the transactivation domain of CREB: A model for activator:coactivator interactions. Cell 91: 741-752.
54. Dames SA, Martinez-Yamout M, De Guzman RN, Dyson HJ, Wright PE, (2002) Structural basis for Hif-1 alpha/CBP recognition in the cellular hypoxic response. Proc Natl Acad Sci USA 99: 5271-5276.
55. Freedman SJ, Sun ZY, Poy F, Kung AL, Livingston DM, et al. (2002) Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci USA 99: 5367-5372.
56. Wojciak JM, Martinez-Yamout MA, Dyson HJ, Wright PE, (2009) Structural basis for recruitment of CBP/p300 coactivators by STAT1 and STAT2 transactivation domains. EMBO J 28: 948-958.
57. Dahlmanwright K, Baumann H, Mcewan IJ, Almlof T, Wright APH, et al. (1995) Structural Characterization of a Minimal Functional Transactivation Domain from the Human Glucocorticoid Receptor. Proc Natl Acad Sci USA 92: 1699-1703.
58. De Guzman RN, Martinez-Yamout MA, Dyson HJ, Wright PE, (2004) Interaction of the TAZ1 domain of the CREB-binding protein with the activation domain of CITED2: regulation by competition between intrinsically unstructured ligands for non-identical binding sites. J Biol Chem 279: 3042-3049.
59. Dyson HJ, Wright PE, (2002) Coupling of folding and binding for unstructured proteins. Curr Opin Struc Biol 12: 54-60.
60. Dyson HJ, Wright PE, (2005) Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol 6: 197-208.
61. Ferreon JC, Martinez-Yamout MA, Dyson HJ, Wright PE, (2009) Structural basis for subversion of cellular control mechanisms by the adenoviral E1A oncoprotein. Proc Natl Acad Sci USA 106: 13260-13265.
62. Dyson HJ, Wright PE, (2004) Unfolded proteins and protein folding studied by NMR. Chemical Reviews 104: 3607-3622.
63. Lee H, Mok KH, Muhandiram R, Park KH, Suk JE, et al. (2000) Local structural elements in the mostly unstructured transcriptional activation domain of human p53. J Biol Chem 275: 29426-29432.
64. Feng HQ, Jenkins LMM, Durell SR, Hayashi R, Mazur SJ, et al. (2009) Structural Basis for p300 Taz2-p53 TAD1 Binding and Modulation by Phosphorylation. Structure 17: 202-210.
65. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953.
66. O'Connor MJ, Zimmermann H, Nielsen S, Bernard HU, Kouzarides T, (1999) Characterization of an E1A-CBP interaction defines a novel transcriptional adapter motif (TRAM) in CBP/p300. J Virol 73: 3574-3581.
67. Miller M, Dauter Z, Cherry S, Tropea JE, Wlodawer A, (2009) Structure of the Taz2 domain of p300: insights into ligand binding. Acta Crystallogr Sect D-Biol Crystallogr 65: 1301-1308.
68. He J, Ye J, Cai YF, Riquelme C, Liu JO, et al. (2011) Structure of p300 bound to MEF2 on DNA reveals a mechanism of enhanceosome assembly. Nucleic Acids Res 39: 4464-4474.
69. Oberer M, Marintchev A, Wagner G, (2005) Structural basis for the enhancement of eIF4A helicase activity by eIF4G. Genes Dev 19: 2212-2223.
70. Zor T, De Guzman RN, Dyson HJ, Wright PE, (2004) Solution structure of the KIX domain of CBP bound to the transactivation domain of c-Myb. J Mol Biol 337: 521-534.
71. Bryson K, McGuffin LJ, Marsden RL, Ward JJ, Sodhi JS, et al. (2005) Protein structure prediction servers at university college london. Nucleic Acids Res 33: W36-W38.
72. Jones DT, (1999) Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol 292: 195-202.